GlassScriptPhysician profile
David M Spector
NPI 1891754404
$16,960.42
in general payments reported to CMS, 2019-2025
68 companies · $4,059 in 2025
The $4,059 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,278 · 2020: $914 · 2021: $1,307 · 2022: $2,443 · 2023: $1,805 · 2024: $4,154 · 2025: $4,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,850 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,849.90 |
| Education | $168.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,724.58 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Daiichi Sankyo INC. | $1,215.23 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $1,183.33 | 2019-2025 | |
| Janssen Biotech, INC. | $1,073.28 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Genzyme Corporation | $844.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $804.91 | 2019-2025 | Opdivo, Pomalyst, Opdualag |
| Lilly USA, LLC | $727.37 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $684.19 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Beigene USA, INC. | $546.73 | 2021-2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $541.05 | 2022-2024 | Zepzelca |
| Takeda Pharmaceuticals U.S.A., INC. | $485.94 | 2019-2025 | Fruzaqla, Hyqvia, Iclusig |
| Amgen INC. | $437.26 | 2019-2025 | Blincyto, Kyprolis |
| Abbvie INC. | $431.21 | 2020-2025 | |
| Pfizer INC. | $425.05 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $418.21 | 2019-2025 | Keytruda, Welireg, Lynparza |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.